Séminaire de Denis Barritault
Invité par Claudia Montero
Le 30 avril 2015
Un séminaire sera donné par Denis Barritault, University Paris Est, Creteil and OTR3.
Les étudiants souhaitant assister à la conférence doivent s'inscrire au préalable avant le Jeudi 29 Avril à 12h00 dans la limite des places disponibles (inscription) (secr-inserm-angers @ contact.univ-angers.fr) en communiquant leur numéro de carte étudiante.
Pour que la participation au séminaire soit validante, il est impératif que les étudiants émargent la feuille de présence.
Pour rappel, les étudiants non inscrits ne seront pas acceptés.
12h00 - 13h00
Amphithéâtre 200 - Faculté de médecine
secr-inserm-angers@contact.univ-angers.fr
« Les Héparanes Sulfates régulateur de l'homéostasie tissulaire. Histoire d'une recherche fondamentale à la clinique et des développements cliniques des mimétiques RGTA en médecine régénérative»
Heparan sulfates (HS) are key elements of the extracellular matrix (ECM), wich store and protect various cell communication peptides (CCP). HS play a central role in tissue homeostasis, by modulating the bioavailability of CCP hence controlling the cell migration and differentiation required for healing processes. Tissue injury will lead to destruction of cells and surrounding ECM are destroyed. CCPs synthesized by inflammatory and circulating cells can then promote tissue repair, but with a loss of tissue quality, leaving scars or fibroses. We have engineered biodegradable nanopolymers mimicking the HS. They bind to the structure proteins of the damaged ECM, and to the CCP produced by healthy neighboring cells, thereby restoring the ECM microenvironment and tissue homeostasis. This matrix therapy approach has improved the quality of healing in various animal models with reduction or absence of fibrosis resulting in a real regeneration process. These HS mimetics have therefore been named RGTA, for ReGeneraTing Agents. The RGTA technology has been validated in over published preclinical studies and is now marketed as a human healing agent both for corneal under trade name of CACICOL and skin ulcers under trade name of CACIPLIQ.. Currently over 20000 patients have been treated.
RGTA are in development for more tissue injuries including mucositis, tendonitis, periodontitis, Inflammatory Bowel disease, bone fracture, muscle ischemia and brain injury. Altogethers these study underline the potential of RGTAs as a new therapeutic class in the field of regenerative medicine, simple safe and exploiting our natural potential without need for exogenous cells supply but can combine with cell therapy to restore cellular microenvironment and homing.